Pacira BioSciences, Inc. Common Stock (PCRX)

Price$22.75

Value ScoreB

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-11.40%

Price vs S&P 500 (4W)-1.72%

VGM Score54.49

Market Capitalization$894.87M

P/E Ratio (Annual)127.22x

All Metrics

P/CF (Annual)5.89x

Book Value / Share (Quarterly)$16.63

P/TBV (Annual)3.43x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)2.90%

Cash Flow / Share (Quarterly)$3.38

Price vs S&P 500 (YTD)-20.25%

Gross Margin (TTM)79.34%

Net Profit Margin (TTM)0.70%

EPS (TTM)$0.13

10-Day Avg Trading Volume0.45M

EPS Excl Extra (TTM)$0.13

Revenue Growth (5Y)11.08%

EPS (Annual)$0.16

ROI (Annual)0.66%

Gross Margin (Annual)79.39%

Net Profit Margin (5Y Avg)0.63%

Cash / Share (Quarterly)$5.14

P/E Basic Excl Extra (TTM)174.17x

Revenue Growth QoQ (YoY)5.00%

EPS Growth (5Y)-45.77%

P/E Normalized (Annual)127.22x

ROA (Last FY)0.56%

Revenue Growth TTM (YoY)4.57%

EBITD / Share (TTM)$1.34

ROE (5Y Avg)0.17%

Operating Margin (TTM)0.15%

Cash Flow / Share (Annual)$3.32

P/B Ratio1.37x

P/B Ratio (Quarterly)1.40x

Net Income / Employee (Annual)$8,500

EV / Revenue (TTM)1.52x

Net Interest Coverage (TTM)7.96x

ROA (TTM)0.39%

EPS Growth QoQ (YoY)-31.04%

EV / EBITDA (TTM)19.14x

EPS Incl Extra (Annual)$0.16

Current Ratio (Annual)4.54x

Quick Ratio (Quarterly)3.01x

3-Month Avg Trading Volume0.67M

52-Week Price Return-14.92%

EV / Free Cash Flow (Annual)8.18x

P/E Incl Extra (TTM)174.17x

Revenue / Employee (TTM)$886,400

Tangible BV / Share (Quarterly)$7.65

P/S Ratio (Annual)1.23x

Asset Turnover (Annual)0.57x

52-Week High$27.64

Operating Margin (5Y Avg)5.54%

EPS Excl Extra (Annual)$0.16

CapEx CAGR (5Y)-16.51%

Tangible BV CAGR (5Y)-9.08%

26-Week Price Return-3.48%

Quick Ratio (Annual)3.01x

13-Week Price Return-0.48%

Total Debt / Equity (Annual)0.54x

Current Ratio (Quarterly)4.73x

Enterprise Value$1.12B

Revenue / Share Growth (5Y)10.41%

Asset Turnover (TTM)0.55x

Book Value / Share Growth (5Y)3.47%

Revenue / Employee (Annual)$876,200

Inventory Turnover (Annual)1.08x

Pretax Margin (Annual)2.32%

Cash / Share (Annual)$5.80

3-Month Return Std Dev33.70%

Gross Margin (5Y Avg)74.39%

Net Income / Employee (TTM)$6,200

EBITDA CAGR (5Y)6.90%

EBITDA Interim CAGR (5Y)-13.73%

ROE (Last FY)1.01%

Net Interest Coverage (Annual)2.65x

EPS Basic Excl Extra (Annual)$0.16

P/FCF (TTM)6.74x

Receivables Turnover (TTM)6.38x

EV / Free Cash Flow (TTM)8.43x

Total Debt / Equity (Quarterly)0.56x

EPS Incl Extra (TTM)$0.13

Receivables Turnover (Annual)6.12x

ROI (TTM)0.45%

P/S Ratio (TTM)1.22x

Pretax Margin (5Y Avg)2.97%

Revenue / Share (Annual)$16.13

Tangible BV / Share (Annual)$7.90

Forward P/E7.32x

Free OCF CAGR (5Y)28.37%

Price vs S&P 500 (52W)-39.29%

P/E Ratio (TTM)174.17x

Year-to-Date Return-12.09%

5-Day Price Return-0.91%

EPS Normalized (Annual)$0.16

ROA (5Y Avg)-0.04%

Net Profit Margin (Annual)0.97%

Month-to-Date Return-2.02%

Cash Flow / Share (TTM)$1.93

EBITD / Share (Annual)$1.43

EPS Growth (3Y)-22.98%

Operating Margin (Annual)0.99%

LT Debt / Equity (Annual)0.54x

P/CF (TTM)6.29x

ROI (5Y Avg)-0.04%

P/E Excl Extra (TTM)174.17x

LT Debt / Equity (Quarterly)0.56x

EPS Basic Excl Extra (TTM)$0.13

P/TBV (Quarterly)3.04x

P/B Ratio (Annual)1.61x

Inventory Turnover (TTM)1.07x

Pretax Margin (TTM)1.79%

Book Value / Share (Annual)$16.86

Price vs S&P 500 (13W)-8.74%

Net Margin Growth (5Y)-50.86%

Beta0.28x

P/FCF (Annual)6.55x

Revenue / Share (TTM)$17.96

ROE (TTM)0.73%

52-Week Low$18.80

vGradeB

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.60est. 0.57

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.85

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PCRXPacira BioSciences, Inc. Common Stock	B	C	C	$22.75
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Pacira BioSciences develops and commercializes non-opioid pain management and regenerative health solutions. The company's marketed products include EXPAREL for postsurgical pain management, ZILRETTA for osteoarthritis, and iovera, a handheld device providing drug-free pain relief through controlled cold therapy. Pacira is also advancing PCRX-201, a gene therapy candidate for knee osteoarthritis.